open access

Vol 6, No 1 (2010)
Guidelines / Expert consensus
Published online: 2010-05-06
Get Citation

The treatment of primary cutaneous lymphoma. Recommendations of the Polish Lymphoma Research Group (PLRG)

Małgorzata Sokołowska-Wojdyło, Ewa Lech-Marańda, Waldemar Placek, Janusz Meder, Jan Maciej Zaucha, Jan Walewski w imieniu Polskiej Grupy Ba Chłoniaków
Onkol. Prak. Klin 2010;6(1):29-47.

open access

Vol 6, No 1 (2010)
EXPERTS' OPINION
Published online: 2010-05-06

Abstract

Primary cutaneous lymphoma is a heterogenous group of lymphoid neoplasms, mostly of T-cell origin, defined by the initial and clinically dominant involvement of skin. Clinical course and prognosis of these diseases is distinct from other nodal or extranodal lymphomas. Cutaneous lymphomas have usually very prolonged course and are incurable in most of the cases. The diagnosis and treatment planning is best applied if multidisciplinary approach involving dermatologists, oncologists, hematologists and pathologists is adopted. Cutaneous Lymphoma Section, created within the Polish Lymphoma Research Group in 2009 set out to reach a consensus on treatment guidelines that would be acknowledged by major specialties involved in the management of these patients. The guidelines are consistent with published international recommendations and supported by current practice of the Polish dermatology and hemato-oncology centers.

Abstract

Primary cutaneous lymphoma is a heterogenous group of lymphoid neoplasms, mostly of T-cell origin, defined by the initial and clinically dominant involvement of skin. Clinical course and prognosis of these diseases is distinct from other nodal or extranodal lymphomas. Cutaneous lymphomas have usually very prolonged course and are incurable in most of the cases. The diagnosis and treatment planning is best applied if multidisciplinary approach involving dermatologists, oncologists, hematologists and pathologists is adopted. Cutaneous Lymphoma Section, created within the Polish Lymphoma Research Group in 2009 set out to reach a consensus on treatment guidelines that would be acknowledged by major specialties involved in the management of these patients. The guidelines are consistent with published international recommendations and supported by current practice of the Polish dermatology and hemato-oncology centers.
Get Citation

Keywords

primary cutaneous lymphoma; primary cutaneous lymphoma classification; topical therapies; systemic treatment; recommendations

About this article
Title

The treatment of primary cutaneous lymphoma. Recommendations of the Polish Lymphoma Research Group (PLRG)

Journal

Oncology in Clinical Practice

Issue

Vol 6, No 1 (2010)

Article type

Guidelines / Expert consensus

Pages

29-47

Published online

2010-05-06

Bibliographic record

Onkol. Prak. Klin 2010;6(1):29-47.

Keywords

primary cutaneous lymphoma
primary cutaneous lymphoma classification
topical therapies
systemic treatment
recommendations

Authors

Małgorzata Sokołowska-Wojdyło
Ewa Lech-Marańda
Waldemar Placek
Janusz Meder
Jan Maciej Zaucha
Jan Walewski w imieniu Polskiej Grupy Ba Chłoniaków

References (127)
  1. Willemze R, Jaffe ES, Burg G, et al. WHO-EORTC classification for cutaneous lymphomas. Blood. 2005; 105(10): 3768–3785.
  2. Swerdlow SH, Campo E, Harris NL. WHO classification of tumours of hematopoietic and lymphoid tissues. International Agency for Research on Cancer (IARC), Lyon 2008: 179–317.
  3. Gniadecki R. Zasady leczenia pierwotnych chłoniaków skóry. Onkologia w Praktyce Klinicznej. 2009; 3: 103–108.
  4. Prince HM, Whittaker S, Hoppe RT. How I treat mycosis fungoides and Sézary syndrome. Blood. 2009; 114(20): 4337–4353.
  5. Duarte RF, Schmitz N, Servitje O, et al. Haematopoietic stem cell transplantation for patients with primary cutaneous T-cell lymphoma. Bone Marrow Transplant. 2008; 41(7): 597–604.
  6. Vonderheid EC, Bernengo MG, Burg G, et al. ISCL. Update on erythrodermic cutaneous T-cell lymphoma: report of the International Society for Cutaneous Lymphomas. J Am Acad Dermatol. 2002; 46(1): 95–106.
  7. Zackheim HS, Kashani-Sabet M, Amin S. Topical corticosteroids for mycosis fungoides. Experience in 79 patients. Arch Dermatol. 1998; 134(8): 949–954.
  8. Herrmann JJ, Roenigk HH, Hurria A, et al. Treatment of mycosis fungoides with photochemotherapy (PUVA): long-term follow-up. J Am Acad Dermatol. 1995; 33(2 Pt 1): 234–242.
  9. Wolska H. Metody fototerapii. W: Fototerapia w dermatologii. Wyd. Czelej, Lublin 2006: 19–46.
  10. Berthelot C, Rivera A, Duvic M. Skin directed therapy for mycosis fungoides: a review. J Drugs Dermatol. 2008; 7(7): 655–666.
  11. Carter J, Zug KA. Phototherapy for cutaneous T-cell lymphoma: online survey and literature review. J Am Acad Dermatol. 2009; 60(1): 39–50.
  12. Hofer A, Cerroni L, Kerl H, et al. Narrowband (311-nm) UV-B therapy for small plaque parapsoriasis and early-stage mycosis fungoides. Arch Dermatol. 1999; 135(11): 1377–1380.
  13. Gathers RC, Scherschun L, Malick F, et al. Narrowband UVB phototherapy for early-stage mycosis fungoides. J Am Acad Dermatol. 2002; 47(2): 191–197.
  14. Rupoli S, Barulli S, Guiducci B, et al. Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group. Haematologica. 1999; 84(9): 809–813.
  15. Stadler R, Otte HG, Luger T, et al. Prospective randomized multicenter clinical trial on the use of interferon -2a plus acitretin versus interferon -2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood. 1998; 92(10): 3578–3581.
  16. Thomsen K, Hammar H, Molin L, et al. Retinoids plus PUVA (RePUVA) and PUVA in mycosis fungoides, plaque stage. A report from the Scandinavian Mycosis Fungoides Group. Acta Derm Venereol. 1989; 69(6): 536–538.
  17. Quirós PA, Jones GW, Kacinski BM, et al. Total skin electron beam therapy followed by adjuvant psoralen/ultraviolet-A light in the management of patients with T1 and T2 cutaneous T-cell lymphoma (mycosis fungoides). Int J Radiat Oncol Biol Phys. 1997; 38(5): 1027–1035.
  18. Hoppe RT, Abel EA, Deneau DG, et al. Mycosis fungoides: management with topical nitrogen mustard. J Clin Oncol. 1987; 5(11): 1796–1803.
  19. Vonderheid EC, Tan ET, Kantor AF, et al. Long-term efficacy, curative potential, and carcinogenicity of topical mechlorethamine chemotherapy in cutaneous T cell lymphoma. J Am Acad Dermatol. 1989; 20(3): 416–428.
  20. Kim YH, Martinez G, Varghese A, et al. Topical nitrogen mustard in the management of mycosis fungoides: update of the Stanford experience. Arch Dermatol. 2003; 139(2): 165–173.
  21. Chinn DM, Chow S, Kim YH, et al. Total skin electron beam therapy with or without adjuvant topical nitrogen mustard or nitrogen mustard alone as initial treatment of T2 and T3 mycosis fungoides. Int J Radiat Oncol Biol Phys. 1999; 43(5): 951–958.
  22. Wilson LD, Jones GW, Kim D, et al. Experience with total skin electron beam therapy in combination with extracorporeal photopheresis in the management of patients with erythrodermic (T4) mycosis fungoides. J Am Acad Dermatol. 2000; 43(1 Pt 1): 54–60.
  23. Duvic M, Olsen EA, Omura GA, et al. A phase III, randomized, double-blind, placebo-controlled study of peldesine (BCX-34) cream as topical therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2001; 44(6): 940–947.
  24. Leman JA, Dick DC, Morton CA. Topical 5-ALA photodynamic therapy for the treatment of cutaneous T-cell lymphoma. Clin Exp Dermatol. 2002; 27(6): 516–518.
  25. Deeths MJ, Chapman JT, Dellavalle RP, et al. Treatment of patch and plaque stage mycosis fungoides with imiquimod 5% cream. J Am Acad Dermatol. 2005; 52(2): 275–280.
  26. Abeni D, Frontani M, Sampogna F, et al. Circulating CD8+ lymphocytes, white blood cells, and survival in patients with mycosis fungoides. Br J Dermatol. 2005; 153(2): 324–330.
  27. Knobler RM, Trautinger F, Radaszkiewicz T, et al. Treatment of cutaneous T cell lymphoma with a combination of low-dose interferon alfa-2b and retinoids. J Am Acad Dermatol. 1991; 24(2 Pt 1): 247–252.
  28. Zhang C, Duvic M. Retinoids: therapeutic applications and mechanisms of action in cutaneous T-cell lymphoma. Dermatol Ther. 2003; 16(4): 322–330.
  29. Talpur R, Ward S, Apisarnthanarax N, et al. Optimizing bexarotene therapy for cutaneous T-cell lymphoma. J Am Acad Dermatol. 2002; 47(5): 672–684.
  30. Duvic M, Hymes K, Heald P, et al. Bexarotene Worldwide Study Group. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol. 2001; 19(9): 2456–2471.
  31. Duvic M, Martin AG, Kim Y, et al. Worldwide Bexarotene Study Group. Phase 2 and 3 clinical trial of oral bexarotene (Targretin capsules) for the treatment of refractory or persistent early-stage cutaneous T-cell lymphoma. Arch Dermatol. 2001; 137(5): 581–593.
  32. Gniadecki R, Assaf C, Bagot M, et al. The optimal use of bexarotene in cutaneous T-cell lymphoma. British Journal of Dermatology. 2007; 157(3): 433–440.
  33. Breneman D, Duvic M, Kuzel T, et al. Phase 1 and 2 Trial of Bexarotene Gel for Skin-Directed Treatment of Patients With Cutaneous T-Cell Lymphoma. Archives of Dermatology. 2002; 138(3): 1386.
  34. Zackheim HS, Kashani-Sabet M, McMillan A. Low-dose methotrexate to treat mycosis fungoides: a retrospective study in 69 patients. J Am Acad Dermatol. 2003; 49(5): 873–878.
  35. McDonald CJ, Bertino JR. Treatment of mycosis fungoides lymphoma: effectiveness of infusions of methotrexate followed by oral citrovorum factor. Cancer Treat Rep. 1978; 62(7): 1009–1014.
  36. Avilés A, Nambo MJ, Neri N, et al. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome. Cancer Biother Radiopharm. 2007; 22(6): 836–840.
  37. Kaye FJ, Bunn PA, Steinberg SM, et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med. 1989; 321(26): 1784–1790.
  38. Mann BS, Johnson JR, He K, et al. Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma. Clin Cancer Res. 2007; 13(8): 2318–2322.
  39. Piekarz RL, Frye R, Turner M, et al. Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma. J Clin Oncol. 2009; 27(32): 5410–5417.
  40. Prince HM, Bishton MJ, Johnstone RW. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol. 2009; 5(5): 601–612.
  41. Gimsing P. Belinostat: a new broad acting antineoplastic histone deacetylase inhibitor. Expert Opin Investig Drugs. 2009; 18(4): 501–508.
  42. Bernengo MG, Quaglino P, Comessatti A, et al. Low-dose intermittent alemtuzumab in the treatment of Sézary syndrome: clinical and immunologic findings in 14 patients. Haematologica. 2007; 92(6): 784–794.
  43. Enblad G, Hagberg H, Erlanson M, et al. A pilot study of alemtuzumab (anti-CD52 monoclonal antibody) therapy for patients with relapsed or chemotherapy-refractory peripheral T-cell lymphomas. Blood. 2004; 103(8): 2920–2924.
  44. Kennedy GA, Seymour JF, Wolf M, et al. Treatment of patients with advanced mycosis fungoides and Sézary syndrome with alemtuzumab. Eur J Haematol. 2003; 71(4): 250–256.
  45. Thursky KA, Worth LJ, Seymour JF, et al. Spectrum of infection, risk and recommendations for prophylaxis and screening among patients with lymphoproliferative disorders treated with alemtuzumab*. Br J Haematol. 2006; 132(1): 3–12.
  46. Gautschi O, Blumenthal N, Streit M, et al. Successful treatment of chemotherapy-refractory Sézary syndrome with alemtuzumab (Campath-1H). Eur J Haematol. 2004; 72(1): 61–63.
  47. Fisher DC, Tawa M. Walsh MClark R.A., Kupper T.S. Low-Dose Alemtuzumab Is Uniquely Effective in Refractory Leukemic Cutaneous T Cell Lymphoma (L-CTCL). ASH Annual Meeting Abstracts. 2009; 114: 3748–3751.
  48. Harland CC, Balsitis M, Millard LG. Sézary-type cutaneous T-cell leukaemia. Response to Winkelmann regimen. Acta Derm Venereol. 1990; 70(3): 251–253.
  49. Zinzani PL, Baliva G, Magagnoli M, et al. Gemcitabine treatment in pretreated cutaneous T-cell lymphoma: experience in 44 patients. J Clin Oncol. 2000; 18(13): 2603–2606.
  50. Duvic M, Talpur R, Wen S, et al. Phase II evaluation of gemcitabine monotherapy for cutaneous T-cell lymphoma. Clin Lymphoma Myeloma. 2006; 7(1): 51–58.
  51. Wollina U, Dummer R, Brockmeyer NH, et al. Multicenter study of pegylated liposomal doxorubicin in patients with cutaneous T-cell lymphoma. Cancer. 2003; 98(5): 993–1001.
  52. Quereux G, Marques S, Nguyen JM, et al. Prospective multicenter study of pegylated liposomal doxorubicin treatment in patients with advanced or refractory mycosis fungoides or Sézary syndrome. Arch Dermatol. 2008; 144(6): 727–733.
  53. Tani M, Fina M, Alinari L, et al. Phase II trial of temozolomide in patients with pretreated cutaneous T-cell lymphoma. Haematologica. 2005; 90(9): 1283–1284.
  54. Sors A, Jean-Louis F, Pellet C, et al. Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood. 2006; 107(6): 2354–2363.
  55. Zinzani PL, Musuraca G, Tani M, et al. Phase II trial of proteasome inhibitor bortezomib in patients with relapsed or refractory cutaneous T-cell lymphoma. J Clin Oncol. 2007; 25(27): 4293–4297.
  56. Fierro MT, Quaglino P, Savoia P, et al. Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: a clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma. 1998; 31(5-6): 583–588.
  57. Akpek G, Koh HK, Bogen S, et al. Chemotherapy with etoposide, vincristine, doxorubicin, bolus cyclophosphamide, and oral prednisone in patients with refractory cutaneous T-cell lymphoma. Cancer. 1999; 86(7): 1368–1376.
  58. Mebazaa A, Dupuy A, Rybojad M, et al. ESHAP for primary cutaneous T-cell lymphomas: efficacy and tolerance in 11 patients. Hematol J. 2005; 5(7): 553–558.
  59. Diamandidou E, Colome-Grimmer M, Fayad L, et al. Transformation of mycosis fungoides/Sezary syndrome: clinical characteristics and prognosis. Blood. 1998; 92(4): 1150–1159.
  60. Vergier B, de Muret A, Beylot-Barry M, et al. Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas. Blood. 2000; 95(7): 2212–2218.
  61. Arulogun SO, Prince HM, Ng J, et al. Long-term outcomes of patients with advanced-stage cutaneous T-cell lymphoma and large cell transformation. Blood. 2008; 112(8): 3082–3087.
  62. Talpur R, Bassett R, Duvic M. Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sézary syndrome. Br J Dermatol. 2008; 159(1): 105–112.
  63. Jackow CM, Cather JC, Hearne V, et al. Association of erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion. Blood. 1997; 89(1): 32–40.
  64. Oliven A, Shechter Y. Extracorporeal photopheresis: a review. Blood Rev. 2001; 15(2): 103–108.
  65. Dani T, Knobler R. Extracorporeal photoimmunotherapy-photopheresis. Front Biosci. 2009; 14: 4769–4777.
  66. Scarisbrick JJ, Taylor P, Holtick U, et al. Photopheresis Expert Group. U.K. consensus statement on the use of extracorporeal photopheresis for treatment of cutaneous T-cell lymphoma and chronic graft-versus-host disease. Br J Dermatol. 2008; 158(4): 659–678.
  67. van Doorn R, Scheffer E, Willemze R. Follicular mycosis fungoides, a distinct disease entity with or without associated follicular mucinosis: a clinicopathologic and follow-up study of 51 patients. Arch Dermatol. 2002; 138(2): 191–198.
  68. Willemze R, Kerl H, Sterry W, et al. EORTC classification for primary cutaneous lymphomas: a proposal from the Cutaneous Lymphoma Study Group of the European Organization for Research and Treatment of Cancer. Blood. 1997; 90(1): 354–371.
  69. Berti E, Tomasini D, Vermeer MH, et al. Primary cutaneous CD8-positive epidermotropic cytotoxic T cell lymphomas. A distinct clinicopathological entity with an aggressive clinical behavior. Am J Pathol. 1999; 155(2): 483–492.
  70. Mielke V, Wolff HH, Winzer M, et al. Localized and disseminated pagetoid reticulosis. Diagnostic immunophenotypical findings. Arch Dermatol. 1989; 125(3): 402–406.
  71. LeBoit PE. Granulomatous slack skin. Dermatol Clin. 1994; 12: 375–389.
  72. van Haselen CW, Toonstra J, van der Putte SJ, et al. Granulomatous slack skin. Report of three patients with an updated review of the literature. Dermatology. 1998; 196(4): 382–391.
  73. Clarijs M, Poot F, Laka A, et al. Granulomatous slack skin: treatment with extensive surgery and review of the literature. Dermatology. 2003; 206(4): 393–397.
  74. Burg G, Kempf W, Cozzio A, et al. WHO/EORTC classification of cutaneous lymphomas 2005: histological and molecular aspects. J Cutan Pathol. 2005; 32(10): 647–674.
  75. Zackheim HS, Epstein EH. Low-dose methotrexate for the Sézary syndrome. J Am Acad Dermatol. 1989; 21(4 Pt 1): 757–762.
  76. Bekkenk MW, Geelen FA, van Voorst Vader PC, et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: a report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood. 2000; 95(12): 3653–3661.
  77. Vonderheid EC, Sajjadian A, Kadin ME. Methotrexate is effective therapy for lymphomatoid papulosis and other primary cutaneous CD30-positive lymphoproliferative disorders. J Am Acad Dermatol. 1996; 34(3): 470–481.
  78. Kadin ME, Carpenter C. Systemic and primary cutaneous anaplastic large cell lymphomas. Semin Hematol. 2003; 40(3): 244–256.
  79. Yamada Y, Tomonaga M. The current status of therapy for adult T-cell leukaemia-lymphoma in Japan. Leuk Lymphoma. 2003; 44(4): 611–618.
  80. Hermine O, Allard I, Lévy V, et al. French ATL therapy group. A prospective phase II clinical trial with the use of zidovudine and interferon-alpha in the acute and lymphoma forms of adult T-cell leukemia/lymphoma. Hematol J. 2002; 3(6): 276–282.
  81. Gonzalez C, Medeiros L, Braziel R, et al. T-Cell Lymphoma Involving Subcutaneous Tissue. The American Journal of Surgical Pathology. 1991; 15(1): 17–27.
  82. Burg G, Dummer R, Wilhelm M, et al. A subcutaneous delta-positive T-cell lymphoma that produces interferon gamma. N Engl J Med. 1991; 325(15): 1078–1081.
  83. Salhany KE, Macon WR, Choi JK, et al. Subcutaneous panniculitis-like T-cell lymphoma: clinicopathologic, immunophenotypic, and genotypic analysis of alpha/beta and gamma/delta subtypes. Am J Surg Pathol. 1998; 22(7): 881–893.
  84. Weenig RH, Ng CS, Perniciaro C. Subcutaneous panniculitis-like T-cell lymphoma: an elusive case presenting as lipomembranous panniculitis and a review of 72 cases in the literature. Am J Dermatopathol. 2001; 23(3): 206–215.
  85. Santucci M, Pimpinelli N, Massi D, et al. EORTC Cutaneous Lymphoma Task Force. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer. 2003; 97(3): 610–627.
  86. Hoque SR, Child FJ, Whittaker SJ, et al. Subcutaneous panniculitis-like T-cell lymphoma: a clinicopathological, immunophenotypic and molecular analysis of six patients. Br J Dermatol. 2003; 148(3): 516–525.
  87. Massone C, Chott A, Metze D, et al. Subcutaneous, blastic natural killer (NK), NK/T-cell, and other cytotoxic lymphomas of the skin: a morphologic, immunophenotypic, and molecular study of 50 patients. Am J Surg Pathol. 2004; 28(6): 719–735.
  88. Cheung MM, Chan JK, Lau WH, et al. Primary non-Hodgkin's lymphoma of the nose and nasopharynx: clinical features, tumor immunophenotype, and treatment outcome in 113 patients. J Clin Oncol. 1998; 16(1): 70–77.
  89. Bekkenk MW, Jansen PM, Meijer CJ, et al. CD56+ hematological neoplasms presenting in the skin: a retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol. 2004; 15(7): 1097–1108.
  90. Agnarsson BA, Vonderheid EC, Kadin ME. Cutaneous T cell lymphoma with suppressor/cytotoxic (CD8) phenotype: identification of rapidly progressive and chronic subtypes. J Am Acad Dermatol. 1990; 22(4): 569–577.
  91. Toro JR, Liewehr DJ, Pabby N, et al. Gamma-delta T-cell phenotype is associated with significantly decreased survival in cutaneous T-cell lymphoma. Blood. 2003; 101(9): 3407–3412.
  92. de Wolf-Peeters C, Achten R. gammadelta T-cell lymphomas: a homogeneous entity? Histopathology. 2000; 36(4): 294–305.
  93. Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol. 2003; 40(3): 175–184.
  94. Grange F, Hedelin G, Joly P, et al. Prognostic factors in primary cutaneous lymphomas other than mycosis fungoides and the Sézary syndrome. The French Study Group on Cutaneous Lymphomas. Blood. 1999; 93(11): 3637–3642.
  95. Beljaards RC, Meijer CJ, Van der Putte SC, et al. Primary cutaneous T-cell lymphoma: clinicopathological features and prognostic parameters of 35 cases other than mycosis fungoides and CD30-positive large cell lymphoma. J Pathol. 1994; 172(1): 53–60.
  96. Bekkenk MW, Vermeer MH, Jansen PM, et al. Peripheral T-cell lymphomas unspecified presenting in the skin: analysis of prognostic factors in a group of 82 patients. Blood. 2003; 102(6): 2213–2219.
  97. Dummer R, Kempf W, Hess Schmid M, et al. Therapy of cutaneous lymphoma--current practice and future developments. Onkologie. 2003; 26(4): 366–372.
  98. Zenahlik P, Fink-Puches R, Kapp KS, et al. [Therapy of primary cutaneous B-cell lymphomas]. Hautarzt. 2000; 51(1): 19–24.
  99. Kirova YM, Piedbois Y, Le Bourgeois JP. Radiotherapy in the management of cutaneous B-cell lymphoma. Our experience in 25 cases. Radiother Oncol. 1999; 52(1): 15–18.
  100. Heinzerling L, Dummer R, Kempf W, et al. Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma. Arch Dermatol. 2000; 136(3): 374–378.
  101. Paul T, Radny P, Kröber SM, et al. Intralesional rituximab for cutaneous B-cell lymphoma. Br J Dermatol. 2001; 144(6): 1239–1243.
  102. Kütting B, Bonsmann G, Metze D, et al. Borrelia burgdorferi-associated primary cutaneous B cell lymphoma: complete clearing of skin lesions after antibiotic pulse therapy or intralesional injection of interferon alfa-2a. J Am Acad Dermatol. 1997; 36(2 Pt 2): 311–314.
  103. Voss N, Kim-Sing C. Radiotherapy in the treatment of dermatologic malignancies. Dermatol Clin. 1998; 16(2): 313–320.
  104. Heinzerling LM, Urbanek M, Funk JO, et al. Reduction of tumor burden and stabilization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphoma. Cancer. 2000; 89(8): 1835–1844.
  105. Gellrich S, Muche JM, Pelzer K, et al. [Anti-CD20 antibodies in primary cutaneous B-cell lymphoma. Initial results in dermatologic patients]. Hautarzt. 2001; 52(3): 205–210.
  106. Sabroe RA, Child FJ, Woolford AJ, et al. Rituximab in cutaneous B-cell lymphoma: a report of two cases. Br J Dermatol. 2000; 143(1): 157–161.
  107. Rijlaarsdam JU, Toonstra J, Meijer OW, et al. Treatment of primary cutaneous B-cell lymphomas of follicle center cell origin: a clinical follow-up study of 55 patients treated with radiotherapy or polychemotherapy. J Clin Oncol. 1996; 14(2): 549–555.
  108. Grange F, Bekkenk MW, Wechsler J, et al. Prognostic factors in primary cutaneous large B-cell lymphomas: a European multicenter study. J Clin Oncol. 2001; 19(16): 3602–3610.
  109. Soda R, Costanzo A, Cantonetti M, et al. Systemic therapy of primary cutaneous B-cell lymphoma, marginal zone type, with rituximab, a chimeric anti-CD20 monoclonal antibody. Acta Derm Venereol. 2001; 81(3): 20720–20728.
  110. Bekkenk MW, Vermeer MH, Geerts ML, et al. Treatment of multifocal primary cutaneous B-cell lymphoma: a clinical follow-up study of 29 patients. J Clin Oncol. 1999; 17(8): 2471–2478.
  111. Cerroni L, Arzberger E, Pütz B, et al. Primary cutaneous follicle center cell lymphoma with follicular growth pattern. Blood. 2000; 95(12): 3922–3928.
  112. Pimpirelli N, Vallecchi C. Local orthovolt radiotherapy in primary cutaneous B-cell lymphomas: results in a series of 115 patients. Skin Cancer. 1999; 14: 219–224.
  113. Piccinno R, Caccialanza M, Berti E. Dermatologic radiotherapy of primary cutaneous follicle center cell lymphoma. Eur J Dermatol. 2003; 13(1): 49–52.
  114. Smith BD, Glusac EJ, McNiff JM, et al. Primary cutaneous B-cell lymphoma treated with radiotherapy: a comparison of the European Organization for Research and Treatment of Cancer and the WHO classification systems. J Clin Oncol. 2004; 22(4): 634–639.
  115. Vermeer MH, Geelen FA, van Haselen CW, et al. Primary cutaneous large B-cell lymphomas of the legs. A distinct type of cutaneous B-cell lymphoma with an intermediate prognosis. Dutch Cutaneous Lymphoma Working Group. Arch Dermatol. 1996; 132(11): 1304–1308.
  116. Brogan BL, Zic JA, Kinney MC, et al. Large B-cell lymphoma of the leg: clinical and pathologic characteristics in a North American series. J Am Acad Dermatol. 2003; 49(2): 223–228.
  117. Ferreri AJM, Campo E, Seymour JF, et al. International Extranodal Lymphoma Study Group (IELSG). Intravascular lymphoma: clinical presentation, natural history, management and prognostic factors in a series of 38 cases, with special emphasis on the 'cutaneous variant'. Br J Haematol. 2004; 127(2): 173–183.
  118. Heese C, Beriwal S, Brady LW, Vonderheid EC. Cutaneous T-cell Lymphoma. In: Halperin EC, Perez CA, Brady LW. ed. Principles and Practice of Radiation Oncology. Wolters Kluwer/Lippincott Wiliams and Wilkins, Philadelphia 2008: 1766–1776.
  119. Jones G, Kacinski B, Wilson L, et al. Total skin electron radiation in the management of mycosis fungoides: Consensus of the European Organization for Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Project Group. Journal of the American Academy of Dermatology. 2002; 47(3): 364–370.
  120. Jarząbski A, Meder J. Kawecki. Zastosowanie metody napromieniania całej skóry wiązką elektronów (total skin electron beam irradiation — TSEBI) w leczeniu ziarniniaka grzybiastego. Nowotwory. 1994; 44: 244.
  121. Rubik A, Jarema A, Rogowska D. Napromienianie elektronami skóry całego ciała w przebiegu Mycosis fungoides. Współcz Onkol. 1999; 3: 123–125.
  122. Bjärngard BE, Chen GT, Piontek RW, et al. Aanlysis of dose distributions in whole body superficial electron therapy. Int J Radiat Oncol Biol Phys. 1977; 2(3-4): 319–324.
  123. Page V, Gardner A, Karzmark CJ. Patient dosimetry in the electron treatment of large superficial lesions. Radiology. 1970; 94(3): 635–641.
  124. Hoppe RT, Cox RS, Fuks Z, et al. Electron-beam therapy for mycosis fungoides: the Stanford University experience. Cancer Treat Rep. 1979; 63(4): 691–700.
  125. Micaily B, Miyamoto C, Kantor G, et al. Radiotherapy for unilesional mycosis fungoides. Int J Radiat Oncol Biol Phys. 1998; 42(2): 361–364.
  126. Micaily B, Moser C, Vonderheid EC, et al. The radiation therapy of early stage mycosis fungoides. Int J Radiat Oncol Biol Phys. 1990; 18: 1333–1339.
  127. Maingon P, Truc G, Dalac S, et al. Radiotherapy of advanced mycosis fungoides: indications and results of total skin electron beam and photon beam irradiation. Radiother Oncol. 2000; 54(1): 73–78.

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Wydawcą serwisu jest  "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl